New target for retinopathy therapy discovered

Article

A variant form of vascular endothelial growth factor (VEGF) has been discovered to be responsible for the inflammation and altered retinal vascularization that occurs in conditions such as diabetic retinopathy.

A variant form of vascular endothelial growth factor (VEGF) has been discovered to be responsible for the inflammation and altered retinal vascularization that occurs in conditions such as diabetic retinopathy (DR), according to an announcement made at the European meeting on Vascular Biology and Medicine in Bristol, England.

Professor David Shima from University College London, UK and co-workers discovered that, although blood vessels in the ischaemic retina re-grow, they do so in a disorganized fashion, forming clumps rather than a fine, mesh-like network. The researchers characterized the VEGF activity responsible for the abnormal response and identified an isoform, VEGF 164, which drives ocular neovascularization, vascular permeability and an inflammatory reaction.

When VEGF 164 was inhibited, either genetically or pharmaceutically, pathological neovascularization was also inhibited and blood vessels were able to form normally. Further investigation found a specific region within VEGF 164 that is a major cause of DR inflammation.

Although this inflammatory function of VEGF 164 represents a target for DR treatment, VEGF has a second, beneficial role in protecting neurons from ischaemic death, so eliminating it completely could trigger unwanted consequences.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.